Randomization
Non‐PD patients who completed four cycles of durvalumab with chemotherapy will be randomized into maintenance phase. Once the patient is confirmed to be eligible to enter maintenance phase, the investigator or suitably trained delegate will obtain a unique randomization number via the interactive voice response system or interactive web response system (IVRS/IWRS). The system will randomize the eligible patient to one of the two treatment arms.